Can you believe ZEPATIER received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7973040 | MSD SUB MERCK | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors |
Jul, 2029
(5 years from now) | |
| US8871759 | MSD SUB MERCK | Inhibitors of hepatitis C virus replication |
May, 2031
(7 years from now) | |
Zepatier is owned by Msd Sub Merck.
Zepatier contains Elbasvir; Grazoprevir.
Zepatier has a total of 2 drug patents out of which 0 drug patents have expired.
Zepatier was authorised for market use on 28 January, 2016.
Zepatier is available in tablet;oral dosage forms.
Zepatier can be used as treatment of patients infected with hepatitis c virus.
Drug patent challenges can be filed against Zepatier from 29 January, 2020.
The generics of Zepatier are possible to be released after 04 May, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 09, 2024 |
| New Chemical Entity Exclusivity(NCE) | Jan 28, 2021 |
Drugs and Companies using ELBASVIR; GRAZOPREVIR ingredient
NCE-1 date: 29 January, 2020
Market Authorisation Date: 28 January, 2016
Treatment: Treatment of patients infected with hepatitis c virus
Dosage: TABLET;ORAL
More Information on Dosage
ZEPATIER family patents
